Risk of Upper Gastrointestinal Complications in Users of Nonsteroidal Antiinflammatory Drugs

First published: 21/10/2011

Last updated: 12/12/2024

Study Finalised

Administrative details

EU PAS number

EUPAS2225

Study ID

5088

DARWIN EU® study

No

Study countries

Italy

Study description

Retrospective cohort study and nested case-control analysis to evaluate the risk of upper gastrointestinal complications (UGIC) in a cohort of patients receiving NSAIDs between 2001-2008 in the Italian region of Friuli Venezia Giulia (FVG). The study was conducted by a research team from RTI Health Solutions, the Institute of Hygiene and Clinical Epidemiology of the University of Udine and University Hospital of Udine, and the Direzione Centrale della Salute, Integrazione Socio Sanitaria e Politiche Sociali, Udine. The study was based on information from the FVG Regional Health Services Databases and hospital medical charts for the validation of cases of UGIC.

The objectives of the study were to

(1) estimate the risk of UGIC associated with the use of nimesulide and other individual NSAIDs,

(2) evaluate the effect of dose and duration of use of individual NSAIDs and the role of potential risk factors for UGIC, and

(3) describe the characteristics of nimesulide users over time.

Study status

Finalised

Research institutions and networks

Institutions

RTI Health Solutions (RTI-HS)

France

Spain

Sweden

United Kingdom



Istituto di Igiene ed Epidemiologia, DSMB Universita' di Udine

☐ Italy

First published: 03/10/2011

Last updated: 17/10/2017



Contact details

Study institution contact

Susana Perez-Gutthann sperez@rti.org

Study contact

sperez@rti.org

Primary lead investigator

Susana Perez-Gutthann

Primary lead investigator

Study timelines

Date when funding contract was signed Actual: 20/10/2009

Study start date Planned: 15/12/2009 Actual: 08/02/2010

Data analysis start date Planned: 01/05/2010 Actual: 01/06/2010

Date of interim report, if expected Actual: 23/03/2011

Date of final study report Planned: 14/02/2011 Actual: 01/07/2011

Sources of funding

• Pharmaceutical company and other private sector

More details on funding

Helsinn Healthcare, S.A.

Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable

Methodological aspects

Study type

Study type list

Study topic:

Human medicinal product

Study type:

Non-interventional study

Scope of the study:

Disease epidemiology Drug utilisation Safety study (incl. comparative)

Data collection methods:

Secondary use of data

Main study objective:

The objectives of the study are to

(1) estimate the risk of UGIC associated with the use of nimesulide and other individual NSAIDs,

(2) evaluate the effect of dose and duration of use of individual NSAIDs and the role of potential risk factors for UGIC, and

(3) describe the characteristics of nimesulide users over time.

Study Design

Non-interventional study design

Case-control Cohort

Study drug and medical condition

Anatomical Therapeutic Chemical (ATC) code

(M01A) ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS

Population studied

Short description of the study population

All residents in the Friuli-Venezia Giulia, Italy (FVG) region with at least 1 year of permanent residence who are prescribed nimesulide or any other NSAID between January 1, 2001, and December 31, 2008

Age groups

Children (2 to < 12 years) Adolescents (12 to < 18 years) Adults (18 to < 46 years) Adults (46 to < 65 years) Adults (65 to < 75 years) Adults (75 to < 85 years) Adults (85 years and over)

Estimated number of subjects

588827

Study design details

Outcomes

Upper gastrointestinal bleeding, perforation, obstruction.

Data analysis plan

Crude age- and sex-specific incidence rates and 95% confidence intervals of UGIC were estimated for current use of NSAIDs and nonuse of NSAIDs. Incidence rates were stratified by history of peptic ulcer and calendar year. The nested case-control analysis was the main analysis of the study. All confirmed cases of UGIC from the study cohort were included in the analysis. Density-based sampling was used to select 10 controls for each case. We used conditional logistic regression to estimate crude and adjusted odds ratios for the risk of UGIC during the periods of exposure to each individual NSAID with the risk during nonuse of NSAIDs.

The model was built manually based on the impact on the effect estimate of NSAIDs and the inclusion of factors associated with increased risk of UGIC, general medical frailty, or with potential selective prescribing of NSAIDs. Effect

measure modification was assessed for age, sex, and concurrent use of aspirin, anticoagulants, and oral corticosteroids.

Documents

Study publications

Castellsague J, Pisa P, Rosolen V, Riera-Guardia N, Giangreco M, Clagnan E, Tos...

Pisa P, Castellsague J, Rosolen V, Riera-Guardia N, Giangreco M, Drigo D, Perez...

Castellsague J, Pisa F, Rosolen V, Drigo D, Riera-Guardia N, Giangreco M, Clagn...

Pisa F, Castellsague J, Drigo D, Riera-Guardia N, Giangreco M, Rosolen V,

Clagn...

Pisa F, Drigo D, Riera-Guardia N, Castellsague J, Rosolen V, Clagnan E, Tosolin...

Data management

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

Data sources

Data sources (types)

Administrative healthcare records (e.g., claims) Drug dispensing/prescription data Other

Data sources (types), other

Hospital medical records

Use of a Common Data Model (CDM)

CDM mapping

No

Data quality specifications

Check conformance

Unknown

Check completeness

Unknown

Check stability

Unknown

Check logical consistency

Unknown

Data characterisation

Data characterisation conducted

No